Expertise in
4
conditions

Linda Aurpibul

Chiang Mai, TH 
Expertise in
4
conditions
Chiang Mai, TH 

Overview

Linda Aurpibul practices practicing medicine in Chiang Mai, Thailand.

Ms. Aurpibul is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses HIV/AIDS, Japanese Encephalitis, Diphtheria, and Hepatitis B.

She is actively involved in clinical research, co-authoring 96 peer reviewed articles and participating in 5 clinical trials.

Gender

Female

Locations

Chiang Mai, Thailand
Other Locations
Wipaporn Natalie Songtaweesin, Is A Faculty Member, Bangkok, Thailand

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Open-label Access to Dolutegravir for HIV-1 Infected Children and Adolescents Completing IMPAACT Studies P1093 and P2019
Open-label Access to Dolutegravir for HIV-1 Infected Children and Adolescents Completing IMPAACT Studies P1093 and P2019
Enrollment Status: Completed
Publish Date: February 05, 2026
Intervention Type: Drug
Study Drugs: Dolutegravir, ABC/DTG/3TC
Study Phase: Phase 3
An Open-label, Single Arm Study to Evaluate the Week 48 Efficacy and Safety of a Two-drug Regimen of Dolutegravir/Lamivudine (DTG/3TC) as a Fixed Dose Combination (FDC), in Antiretroviral Therapy (ART)-Naive HIV-1-infected Adolescents, ≥12 to <18 Years of Age Who Weigh at Least 25 kg
An Open-label, Single Arm Study to Evaluate the Week 48 Efficacy and Safety of a Two-drug Regimen of Dolutegravir/Lamivudine (DTG/3TC) as a Fixed Dose Combination (FDC), in Antiretroviral Therapy (ART)-Naive HIV-1-infected Adolescents, ≥12 to <18 Years of Age Who Weigh at Least 25 kg
Enrollment Status: Completed
Publish Date: December 09, 2025
Intervention Type: Drug
Study Drug: Dolutegravir/Lamivudine
Study Phase: Phase 3
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
Enrollment Status: Terminated
Publish Date: February 20, 2025
Intervention Type: Biological, Drug
Study Drug: RSV Maternal vaccine
Study Phase: Phase 3
A Prospective Epidemiological Study of Pregnancy Outcomes and of Events of Interest in Pregnant Women, Neonates and Infants (PEPNI)
A Prospective Epidemiological Study of Pregnancy Outcomes and of Events of Interest in Pregnant Women, Neonates and Infants (PEPNI)
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Procedure, Other
Study Phase: Not Applicable
Effect of Calcium and High-dose Vitamin D Supplementation on Bone Mineral Density Among Perinatally HIV-infected Children and Adolescents
Effect of Calcium and High-dose Vitamin D Supplementation on Bone Mineral Density Among Perinatally HIV-infected Children and Adolescents
Enrollment Status: Completed
Publish Date: August 08, 2019
Intervention Type: Dietary supplement
Study Phase: Phase 3
View 4 Less Clinical Trials

96 Total Publications

Depression, Anxiety, Stress, Self-Esteem, and HIV-Related Stigma in Adolescents and Young Adults Living With Perinatally Acquired HIV in Northern Thailand.
Depression, Anxiety, Stress, Self-Esteem, and HIV-Related Stigma in Adolescents and Young Adults Living With Perinatally Acquired HIV in Northern Thailand.
Journal: Journal of the International Association of Providers of AIDS Care
Published: May 16, 2026

Frequently Asked Questions about Linda Aurpibul

Is Linda Aurpibul a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Linda Aurpibul is classified as an Elite expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Linda Aurpibul participate in research or clinical trials?

Yes. Linda Aurpibul has published 96 articles and abstracts on conditions like HIV/AIDS. You can view a list of Linda Aurpibul's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Aurpibul's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile